Brief: CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
20/10/2025 14:07
Oct 20 (Reuters) - Redhill Biopharma Ltd 2RHy.F: CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO Source text: ID:nPnbntmspa Further company coverage: [2RHy.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM